Percutaneous coronary intervention and thrombolytic therapy can significantly benefit and improve the prognosis of myocardial infarction patients, but the following problem of myocardial ischemia reperfusion injury is also prominent. Myocardial ischemia reperfusion injury involves multiple target pathways, and the relationship between different signaling pathways is complex. In recent years, reperfusion injury salvage kinase and survivor activating factor enhancement, two novel survival promoting kinase signaling pathways, have emerged as a new target for the treatment of reperfusion intervention, thus becoming a new breakthrough point in cardiovascular diseases and even other vascular diseases. This article aims to explain the mechanism of the protective effects of these two signaling pathways on myocardial ischemia reperfusion, and provide a new approach for the research and development of new drugs for myocardial infarction.